KCNA3 and ischemic stroke: This hypothesis would be in line with the finding that the KV1.3 blocker PAP-1 reduced microglia activation and brain levels of IL‐1β and IFN‐γ, leading to roughly 40% smaller infarct areas and improved neurological deficit scores in both mouse and rat models of ischemic stroke [5].